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Background. Daclizumab (150 kD), a humanized mono-
clonal antibody (mAb) against the alpha-chain of the mem-
brane-bound interleukin-2 (IL-2) receptor (IL-2R) also binds
soluble interleukin-2R  (sIL-2R; 45 kD), and thus may
influence the glomerular filtration of sIL-2R.
Methods. We have studied the influence of daclizumab on
the renal excretion of sIL-2R in 38 recipients of a renal trans-
plant (32 treated with daclizumab and six controls). sIL-2R
was measured every 2 weeks after transplantation in serum
and urine with Immulite IL-2R, a solid-phase enzyme-linked
immunosorbent assay (ELISA).
Results. In the control population, the fractional excretion
of sIL-2R was relatively constant with a median value of
1.7%  0.5%. In daclizumab-treated patients, sIL-2R was
not detectable in the urine immediately after the administration
of daclizumab. sIL-2R became detectable in the urine at a
mean of 8 3 weeks after transplantation. In additional experi-
ments, serum compounds were separated by size-exclusion
chromatography and sIL-2R was measured in the collected
fractions. In the control patients, sIL-2R was only present in
the low-molecular-weight fractions of serum. In contrast, in
daclizumab-treated patients evaluated several weeks after
transplantation, sIL-2R was merely detected in the high-mo-
lecular-weight fractions of serum. During follow-up there was
a relative shift of sIL-2R from the high- to the low-molecular-
weight fractions and this coincided with normalization of sIL-
2R excretion.
Conclusion. Daclizumab inhibits the renal excretion of sIL-
2R by the formation of a complex with sIL-2R in serum,
which is too large for glomerular filtration. Measurement of
urinary sIL-2Rmay provide information on the concentration
of anti-IL-2R mAb in serum.
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Interleukin-2 (IL-2) plays a critical role in the prolifer-
ative expansion of antigen-stimulated T cells, and exerts
its growth promoting action via specific cell membrane
receptors [1]. A low affinity receptor for IL-2, consisting
of a beta and a gamma chain is constitutively expressed
on lymphocytes. Activation of lymphocytes results in co-
expression of the alpha chain of IL-2 receptor (IL-2R
or CD25) leading to the formation of an IL-2 receptor
with a high affinity for IL-2 [2].
Soluble IL-2R (sIL-2R, 45 kD) is the truncated
form of the alpha chain of the IL-2 receptor and is de-
rived from proteolytic cleavage of membrane bound IL-
2R [3, 4]. sIL-2R retains the ability of binding IL-2
with a low affinity [5–7]. sIL-2R is found in the urine
and serum of healthy persons, and increased serum con-
centrations are found in a variety of diseases such as
T-cell leukemia, acquired immunodeficiency syndrome
(AIDS), autoimmune diseases, and after organ trans-
plantation [3, 8]. These increased concentrations are the
result of an increased production and have been pro-
posed to reflect the tumor burden or the rate of immuno-
logic activation. In recipients of organ transplants, high
concentrations were found during acute rejection, cyto-
megalovirus (CMV) infection and after treatment with
antithymocyte globulin. Several studies have reported
that increased concentrations of sIL-2R in serum and
urine may be helpful in detecting acute rejection [9–14],
although other studies have challenged the usefulness of
sIL-2R for this purpose [15, 16]. Normally, 90% of sIL-
2R is catabolized by the kidneys, a process governed
by glomerular filtration and tubular reabsorption [17].
A small amount of filtered sIL-2R escapes tubular reab-
sorption and is excreted in the urine. Administration of
anti-IL-2R antibodies may affect normal renal handling
of sIL-2R by forming a large complex that cannot be
filtered. Indeed, administration of anti-IL-2R mono-
clonal antibodies (mAb) in mice appeared to inhibit the
renal clearance of sIL-2R [17]. Thus far, the effect of
an anti-IL-2R mAb on the renal excretion of sIL-2R
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has not been studied in humans. Daclizumab, a human-
ized monoclonal immunoglobulin G (IgG1) directed
against IL-2R is a competitive inhibitor of IL-2 [18].
Daclizumab has been proven effective for acute rejection
prophylaxis after organ transplantation, and preliminary
results suggest beneficial effects in the treatment of graft-
versus-host disease, uveitis anterior, and refractory pso-
riasis [19–22]. We investigated the influence of daclizu-
mab on the renal excretion of sIL-2R in recipients of
a renal transplant. Our hypothesis was that a decline in
the excretion of sIL-2R reflects the presence of daclizu-
mab in serum. Such a finding might be helpful for thera-
peutic drug monitoring of daclizumab.
METHODS
Study population
The study population consisted of 38 adult patients
who received a renal allograft at the University Medical
Center Nijmegen, The Netherlands. Patients participated
in a prospective randomized controlled trial comparing
induction therapy with daclizumab (1 mg/kg intrave-
nously) on day 0 and day 10 after renal transplantation
with maintenance therapy with prednisone, which was
tapered from 0.3 mg/kg/day to 0 mg/kg/day during the
first 4 months after renal transplantation. Methylpredni-
solone (100 mg intravenously) was given to all patients
during the first 3 days after renal transplantation. The
additional standard immunosuppression consisted of ta-
crolimus and mycophenolate mofetil (750 mg twice a
day). Patients receiving daclizumab (N  32) were com-
pared with prednisone-treated controls (N  6).
Analytic methods
In all patients, peripheral blood and urine samples
were collected preoperatively and approximately every
2 weeks during outpatient follow-up visits after renal
transplantation. Samples of urine produced at 0, 2, 4,
and 6 hours after renal transplantation were collected
in six recipients of a renal transplant with immediate
function (controls, N  3; daclizumab treated, N  3).
Serum was frozen at 20C and urine at 70C until
assays were performed in batches. Two urine samples
that contained more than 1 g/L protein were excluded
from analysis to preclude that the presence of daclizu-
mab in the urine would interfere with the detection of
sIL-2R in the urine.
Enzyme-linked immunosorbent assay (ELISA) for
measurement of sIL-2R
sIL-2R was measured with a commercially available
automated solid-phase, two-site chemiluminescent im-
munometric assay according to the specifications of the
manufacturer (Immulite; DPC, Los Angeles, CA, USA).
This assay employs a murine mAb against the IL-2R
(capture antibody) and a polyclonal anti-IL-2R–detecting
antibody. The values are expressed in units per milliliter
based on the reference standard supplied by the manufac-
turer, with limits of detection between 50 and 7200 U/mL.
Separation of low- versus high-molecular-weight
serum fraction
Serum compounds were separated by size-exclusion
chromatography [23] on a high-load Superdex 75 Col-
umn (prep grade 16/60; Amersham Biosciences, Roosen-
daal, The Netherlands). The Superdex 75 Column opti-
mally fractionated serum compounds with a molecular
weight of3 to 70 kD. Serum compounds with a molecu-
lar weight above 70 kD are not optimally fractionated
and are found in the first elution fractions. We have
calibrated the column using blue dextran ( V0; 2000
kD), IgG (150 kD), albumin (67 kD), ovalbumin
(43 kD), and chymotrypsinogen (25 kD), dissolved
in buffer. Serum samples of 1 mL were diluted two times
with buffer (0.05 mol/L KH2PO4, 0.04 mol/L NaOH, and
0.15 mol/L NaCl; pH  7.4), applied to the column and
eluted with the earlier-mentioned buffer at a flow rate
of 1 mL/min. Elution fractions of 1 mL were collected.
sIL-2R was measured in all separate fractions in one
control patient and compared with the elution pattern
of a daclizumab-treated patient. In three controls and
four daclizumab-treated patients the respective fractions
containing substances with an apparent high molecular
weight (fraction 49 to 57) were combined and fractions
containing substances with an apparent low molecular
weight (fraction 58 to 66) were combined.
Other analysis
Urine and serum specimens were assayed for creati-
nine concentrations by automated methods. Urinary sIL-
2Rwas expressed per millimole of urinary creatinine to
correct for urine flow and sampling errors. The fractional
excretion (FE) of sIL-2Rwas calculated [sIL-2R urine
(U/mL)  creatinine serum (mol/L)]/[sIL-2R serum
(U/mL)  creatinine urine (mmol/L)  1000] and ex-
pressed as percentage.
Statistical analysis
Unless otherwise indicated, results are expressed as
the mean  SD. A Student t test was performed to
compare the maximum serum value of sIL-2R between
groups. A P value less than 0.05 was considered statisti-
cally significant. The statistical software SPSS version
10.0 for Windows was used (SPSS, Chicago, IL,USA).
RESULTS
The characteristics of the patients are shown in Table 1.
In pilot experiments we have measured serum sIL-
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Table 1. Patient characteristics and results after transplantation
Daclizumab
Controls treated
(N  6) (N  32)
Age years 4714 5016
Male number 2 20
LRD/CAD/NHBD number 2/3/1 15/12/5
Acute rejection number 0 2
CMV infection number 1 6
Tacrolimus toxicity number 0 3
Acute tubular necrosis number 1 6
Serum creatininea lmol/L 14854 15232
Abbreviations are: LRD, living related donor; CAD, cadaveric donor; NHBD,
non-heartbeating donor; CMV, cytomegalovirus.
a Three months after transplantation
Fig. 1. Adding increased doses of daclizumab interferes with the detec-
tion of soluble interleukin-2 receptor  (sIL-2R) by the Immulite
assay, probably by competition with the capture antibody of the enzyme-
linked immunosorbent assay (ELISA) for binding sIL-2R. sIL-2R
expressed as a percentage of the value at baseline (without daclizumab)
in serum containing 870 U/mL of sIL-2R. *Limit of detection.
2R levels in the morning and in the afternoon to exclude
a daytime rhythm. No differences were found (989 versus
988 U/mL; N  4). Additionally, we have compared the
sIL-2R/creatinine ratio in morning urine samples with
the sIL-2R/creatinine ratio in 24-hour urine collected
at the same day, and again no major difference was
observed (74 U/mmol versus 75 U/mmol; N  4).
Daclizumab influences the measurement of sIL-2R
by ELISA
To investigate the effect of daclizumab on the mea-
surement of sIL-2R, daclizumab was added in concen-
trations from 0 to 5.0 g/mL to a control serum. As
shown in Figure 1, addition of increased doses of daclizu-
mab decreased the levels of sIL-2R as measured by
the Immulite assay. Thus, the ELISA does not allow
Fig. 2. Elution pattern of soluble interleukin-2 receptor  (sIL-2R)
in a control patient () showing presence of sIL-2R predominantly in
the low-molecular-weight serum fractions. After addition of daclizumab
(0.9 g/mL), sIL-2R was only detectable in the fractions with a high
molecular weight (). sIL-2R values expressed on log scale. *Limit
of detection  50 U/mL; calibration of the column was performed with
blue dextran (V0; 2000 kD), IgG (150 kD), albumin (67 kD),
ovalbumin (43 kD), and chymotrypsinogen (25 kD).
quantitative measurement of the total concentration of
sIL-2R in serum of daclizumab-treated patients. It re-
mained unclear if the ELISA values reflected the concen-
tration of the free sIL-2R in serum.
sIL-2R values in high- and low-molecular-weight
fractions of serum
To determine if the ELISA only detected free sIL-
2R, additional studies were done using size-exclusion
chromatography. As expected, in a control patient, sIL-
2R was detected in the low-molecular-weight serum
fractions (Fig. 2). From Figure 2, it appears that the
apparent molecular weight of the sIL-2R is higher than
expected, most likely the result of some changes in physi-
ochemical properties of sIL-2R in the presence of se-
rum or formation of dimers. In this control patient, the
sum of sIL-2R measured in the different fractions was
similar to the value measured in unfractionated serum,
indicating a good recovery. After addition of daclizumab
to a control serum (concentration of sIL-2R, 1139 U/mL;
final concentration of daclizumab, 0.9 g/mL), the mea-
sured sIL-2R value decreased to 160 U/mL. After frac-
tionating the serum, sIL-2R was only recovered in the
serum fractions with a high molecular weight (Fig. 2).
The sum of sIL-2R measured in the fractions was ap-
proximately three times higher than the value measured
in unfractionated serum and approached the value mea-
sured in the serum before the addition of daclizumab.
The effect of dilution on the ELISA measurements
The difference in sIL-2R values measured before
and after fractionation of daclizumab-containing serum
might be related to dilution during the fractionation pro-
cedure. Therefore, the effect of dilution of serum on
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Fig. 3. The effect of dilution of serum on the measurement of soluble
interleukin-2 receptor  (sIL-2R) by the enzyme-linked immmunosor-
bent assay (ELISA). The values are expressed as a percentage of the
value without dilution: () average of three controls; () average values
of serum taken several weeks after transplantation in two daclizumab-
treated patients. In control patients, dilution of the serum did not affect
the recovery of sIL-2R (i.e., ELISA readings decreased linearly to
the dilution step). In contrast, in daclizumab-treated patients ELISA
readings of diluted serum samples were higher than expected. With
increased dilution, the concentration of daclizumab decreased relative
to the (fixed) concentration of the capture antibody of the ELISA, and
relatively more sIL-2R is measured by the assay due to an increased
dissociation of the sIL-2R-daclizumab complex.
ELISA measurements was studied in vitro. In control
patients, dilution of the serum did not affect the recovery
of sIL-2R (i.e., ELISA readings decreased linearly to
the dilution step) (Fig. 3). In contrast, in daclizumab-
treated patients ELISA readings of diluted serum sam-
ples were higher than expected (Fig. 3). Taken together,
it is evident that in the ELISA the capture antibody
competes with daclizumab for binding of sIL-2R. The
amount of sIL-2R that is detected by the ELISA there-
fore depends on the concentration and the affinity for
sIL-2R of both antibodies. This also explains the in-
crease in recovery of sIL-2R upon dilution of daclizu-
mab containing serum. With increased dilution of serum
the concentration of daclizumab decreases relative to
the (fixed) concentration of the capture antibody of the
ELISA, and relatively more sIL-2R is measured by the
assay due to an increased dissociation of sIL-2R in
complex with daclizumab.
The effect of daclizumab on sIL-2R values in the
urine and serum
In the control patients, the serum concentration of
sIL-2R decreased in parallel with the recovery of renal
function after transplantation and remained stable in the
absence of acute rejections or CMV infections (Fig. 4A).
sIL-2R was detectable in the urine collected immedi-
ately after transplantation (Fig. 5). The fractional excre-
Fig. 4. Time course of the mean ( SE) serum (A) and urinary (B)
concentration of soluble interleukin-2 receptor  (sIL-2R) (adjusted
for urinary creatinine) in six control patients and 32 daclizumab-treated
patients after transplantation. In contrast to the controls, no sIL-2R
is excreted in daclizumab-treated patients in the first weeks after trans-
plantation.
tion of sIL-2R was relatively constant at an average of
1.7%  0.5%.
There was a characteristic pattern of the measured
sIL-2R values in the urine and serum in all daclizumab
treated patients (Fig. 4), which was completely different
from the control population. sIL-2R was undetectable
in the first urine collected immediately after the adminis-
tration of daclizumab (Fig. 5) and urinary sIL-2R re-
mained undetectable for an average of 8 3 weeks after
transplantation. Thereafter, the urinary excretion of sIL-
2R increased to values observed in control patients.
After the administration of daclizumab, the serum value
of measured sIL-2R initially decreased to on average
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Fig. 5. Urinary excretion of soluble interleukin-2 receptor  (sIL-2R)
in three control patients (, , and ) and three patients treated with
daclizumab () in the first hours after transplantation. sIL-2R was
undetectable in all three daclizumab-treated patients.
18%  11% of the baseline value. Subsequently, the
measured sIL-2R serum value increased to an average
maximum of 130%  40% of the baseline value at 15 
2 weeks after renal transplantation and subsequently
decreased for the second time. The peak serum value of
sIL-2R was approximately two times higher than the
maximum serum values measured in controls after renal
transplantation (P  0.01). The pattern of the serum
value of sIL-2R measured as well as the peak serum
value of sIL-2R in daclizumab-treated patients was not
different between patients experiencing (N  6) or not
experiencing (N  26) a CMV infection [average peak
serum level of sIL-2R, 119%  44% versus 133% 
40% of the baseline value (NS)].
Urinary excretion of sIL-2R in relation to the
presence of sIL-2R in different molecular-weight
fractions of serum
In three control patients, sIL-2Rwas merely detected
in the serum fractions with an apparent low molecular
weight (Table 2). In four daclizumab-treated patients,
analyzed 2 weeks before the peak serum value of mea-
sured sIL-2R, sIL-2R was predominantly detectable
in the high-molecular-weight fractions of serum. The
urinary sIL-2R concentration was low at that moment.
The sum of the values of sIL-2R measured in the high-
and low-molecular-weight fractions was up to five times
higher than measured in unfractionated serum. This re-
covery was even higher than described in the in vitro
experiment of Figure 2, indicating substantial accumula-
tion of complexes in these daclizumab-treated patients
analyzed several weeks after transplantation.
Subsequent analysis in two daclizumab-treated pa-
tients with a nearly normalized fractional sIL-2R excre-
tion showed an increase in the proportion of sIL-2R
measured in the low-molecular-weight fraction of serum
(Table 2). As illustrated in Figure 6, a change of the
fractional sIL-2R excretion toward normal coincides
with a relative shift of serum sIL-2R from the high- to
the low-molecular-weight fractions.
DISCUSSION
We have studied the renal handling of sIL-2R in
renal transplant recipients and specifically evaluated the
effect of daclizumab.
Daclizumab is a humanized mAb against the alpha
chain of the IL-2 receptor, which is expressed on the
membrane of activated peripheral lymphocytes. Our
data confirm that in addition to membrane bound IL-
2R, daclizumab also binds to the circulating sIL-2R.
Consequently, measurement of circulating sIL-2R in
daclizumab-treated patients may provide information on
serum levels of daclizumab. However, the ELISA used
for measuring sIL-2R is not able to provide precise
information on either free or total sIL-2R levels. The
detection of sIL-2R in the high-molecular-weight frac-
tion and the increased recovery of sIL-2R after dilution
of serum of daclizumab-treated patients indicate that the
capture antibody of the ELISA and daclizumab compete
for binding of sIL-2R. Binding of free sIL-2R to the
capture antibody in a serum sample that contains a small
amount of sIL-2R in equilibrium with daclizumab-
bound sIL-2Rwill result in some additional dissociation
of the latter complex. Thus, the measured value of sIL-
2R will be higher than the original free concentration
of sIL-2R, but substantially lower than the total amount
of sIL-2R in serum since the sIL-2R-daclizumab com-
plex will not dissociate completely. Unfortunately, there
is no acceptable alternative for the ELISA to determine
the serum concentration of (free) sIL-2R during ther-
apy with daclizumab more accurately.
On theoretic grounds, we have made the assumption
that the detection of sIL-2R in the urine is not influ-
enced by contamination of the urine with daclizumab.
Daclizumab is a humanized IgG, and has the same physi-
cal properties as IgG [24]. The average patient has 50
to 100 g IgG. After the infusion of 150 mg of daclizumab
(2 1 mg/kg body weight),0.3% of the total IgG content
[0.150/(50 	 0.15)  100%] consists of daclizumab. The
average concentration of IgG in the urine is 8 mg/L [25].
Assuming an intact glomerular barrier, the peak concen-
tration of daclizumab in the urine is 0.3%  8 mg/L 
0.02 g/mL. Considering the dose-interference curve of
Figure 1, it is unlikely that such a low concentration of
daclizumab interferes in an important way with the detec-
tion of sIL-2R in the urine. So spilling of daclizumab
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Table 2. Soluble interleukin-2 receptor  (sIL-2R) measurements in the high- and low-molecular-weight serum fractions and the urinary
excretion sIL-2R in daclizumab-treated patients and in controls
Daclizumab treated (N  4)
Controls Before peak After peaka
Measured sIL-2R (N  3) (N  4) (N  2)
Low-molecular-weight fraction U/mL 606–1272 0–720 612–787
High-molecular-weight fraction U/mL 0–420 3612–7056 960–1140
Proportion in low-molecular-weight fractionb 75% to 100% 0% to 10% 39% to 40%
Urinary concentration U/mmol creatinine 73–168 24–51 88–117
Measured fractional excretion % 1.4–2.7 0.3–0.55 1–1.1
Values are expressed as ranges.
a In daclizumab-treated patients, samples were taken before and after the peak of the measured sIL-2R value in serum
b Expressed as a percentage of the sum of sIL-2R recovered in the low- and high-molecular-weight fractions
Fig. 6. Elution pattern of soluble interleukin-2 receptor  (sIL-2R)
in a daclizumab-treated patient showing presence of sIL-2R predomi-
nantly in the high-molecular-weight serum fractions (). The urinary
excretion of sIL-2R at this stage was 28 U/mmol creatinine. This patient
was studied 6 weeks later (), when the urinary excretion of sIL-2R
had increased to 88 U/mmol creatinine (fractional excretion 1.0%).
At this time point, sIL-2R had shifted from the high- to the lower-
molecular-weight fractions of serum. sIL-2R values expressed on log
scale. *Limit of detection  50 U/mL; calibration of the column was
performed with blue dextran (V0; 2000 kD), IgG (150 kD), albu-
min (67 kD), ovalbumin (43 kD), and chymotrypsinogen (25 kD).
in the urine with subsequent inhibition of the ELISA is
unlikely in the absence of a (large) glomerular leak.
In the control population, the serum concentration of
sIL-2R decreased after transplantation compared with
the value before transplantation, which is probably ex-
plained by the recovery of renal function leading to the
elimination of sIL-2R (Fig. 4A) [9, 13, 15]. In accor-
dance to others, we found a relatively low fractional
excretion of 1.7%  0.5%, which suggests tubular reab-
sorption and subsequent catabolism of sIL-2R [14].
In daclizumab-treated patients, however, the renal ex-
cretion of sIL-2R was temporarily completely abol-
ished. This effect was noted immediately after the admin-
istration of daclizumab and lasted up to an average of
8 weeks after renal transplantation. By separating the
serum in a low- and a high-molecular-weight fraction
with size exclusion chromatography, we could relate the
urinary excretion of sIL-2R to the ratio of bound and
free sIL-2R in the serum at different time points. Our
results showed that the urinary excretion of sIL-2Rwas
low when most of sIL-2R was bound to daclizumab (
present in the high-molecular-weight fractions), whereas
the urinary and fractional excretion of sIL-2R restored
to a normal value in parallel with a relative increase of
free sIL-2R. In other words, formation of a complex
of daclizumab and sIL-2R (sIL-2R /anti-IL-2RmAb
complex,200 to 240 kD) which is too large for glomeru-
lar filtration abrogates the metabolism and urinary excre-
tion of sIL-2R during therapy of daclizumab. Although
the ELISA underestimates total sIL-2R levels in serum
of daclizumab-treated patients, higher values were reached
than in controls. This increase in the sIL-2R values
after treatment with daclizumab indicates accumulation
of complexes of sIL-2R and daclizumab. These results
confirm the findings of Junghans and Waldmann [17]
who also found a decreased glomerular filtration and
subsequently decreased renal catabolism in combination
with increased serum levels of total sIL-2R during anti-
IL-2R mAb–directed treatment of mice.
Monitoring of sIL-2R in the serum or urine seems
useless for predicting immunologic activation during
anti-IL-2R–directed mAb therapy. Several patients in
our study experienced a CMV infection. We could not
detect an influence of this stimulus for shedding of sIL-
2R on the pattern of sIL-2R values measured in the
urine or serum. Apparently, the influence of daclizumab
on the renal excretion of sIL-2R is a more important
determinant of the sIL-2R concentration than the in-
creased shedding of sIL-2R associated with a CMV
infection. The same might be true for acute rejections,
but the proportion of patients experiencing an acute
rejection was too small for firm conclusions.
On the other hand, the urinary sIL-2R concentration
reflects the amount of free sIL-2R in the serum, which
probably is inversely correlated to the concentration of
the anti-IL-2R mAb. Therefore, measuring the urinary
excretion of sIL-2R may be useful to make sure that
the concentration of daclizumab is high enough as not
to allow detection of sIL-2R in the urine. The clinical
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relevance of this finding, however, is unclear and remains
to be determined. Measurement of sIL-2R by an auto-
mated ELISA has several advantages above the alterna-
tive ways of therapeutic drug monitoring of daclizumab-
like measurement of the concentration of daclizumab
[26] and flow cytometric analysis of IL-2Rpos lympho-
cytes. It is easier, can be postponed to another more
convenient day, and requires less qualified personnel.
Prospective studies are needed to compare the methods
for the assessment of circulating anti-IL-2R mAbs.
We expect that these results can be extrapolated to
therapy with other mAb-directed against the IL-2R
chain. The structure of sIL-2R is very similar to that
of membrane-bound IL-2R, with similar epitopes [6].
The key factor of the change in catabolism of sIL-2R
is the ability of a mAb to bind sIL-2R with subsequent
formation of a complex of the mAb and sIL-2R, which
is too large to be filtered by the glomerulus. Preliminary
results have shown a comparable pattern of the serum
concentration of sIL-2R after treatment with another
IL-2R–blocking mAb, basiliximab (Kovarik JM, per-
sonal communication).
CONCLUSION
Daclizumab inhibited the renal excretion of sIL-2R.
Measurement of the urinary concentration of sIL-2Rmay
be useful to make sure that enough anti-IL-2R–directed
mAb is present in the circulation to inhibit filtration of
sIL-2R. The clinical relevance of this finding is unclear.
Currently, we are comparing the value of monitoring of
sIl-2R in the urine with flow cytometric analysis of IL-
2Rpos lymphocytes after treatment with daclizumab in
a large cohort of patients.
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